This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650856 | PMC |
| http://dx.doi.org/10.1093/cid/ciae242 | DOI Listing |
Publication Analysis
Top Keywords
long-acting injectable
12
injectable cabotegravir
8
bimonthly long-acting
8
cabotegravir rilpivirine
4
rilpivirine pregnant
4
pregnant woman
4
woman hiv
4
hiv case
4
case report
4
report describes
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!